Introduction
Despite the introduction of innovative therapies that target identified molecular and cellular mechanisms in various cancers, dose intensification remains a useful option for a number of patients with mostly stage II/III multiple myelomas and a variety of lymphomas. 1, 2 Patients receiving high-dose chemotherapy also receive autologous transplantation, which can be performed if they have successful mobilization and collection of hematopoietic stem and progenitor cells from peripheral blood. Mobilization procedures require G-CSF alone or with certain cytotoxic agents, including alkylating agents such as cyclophosphamide. 2 The quantity of collected and then infused autologous CD34 þ cells is a predictor of neutrophil and platelet recovery following high-dose chemotherapy. [3] [4] [5] There is a large interindividual variability in response to mobilizing agents; reasons for this variability are not completely elucidated, and include genetic polymorphisms [6] [7] [8] and elements of medical history, such as the amount and duration of previous myelotoxic treatments. Recently, plerixafor, formerly known as AMD-3100, was shown to be useful in association with G-CSF for a proportion of poorly mobilizing patients. [9] [10] [11] [12] Recombinant human SCF (rhSCF) or ancestim has also been used in this patient subset.
Endogenous SCF is the ligand for c-kit, 13 a membrane receptor with tyrosine kinase activity that is expressed on several tissues, including subsets of the hematopoietic system. SCF is known to induce stem and progenitor cell mobilization from the marrow to the blood compartment. However, its effects on basophils and mastocytes may result in intense allergy-like phenomena, 14 which makes its clinical use less convenient than that of G-CSF. Nevertheless, subcutaneously administered SCF has been used in small series of poorly mobilizing patients, allowing autologous collection and transplantation in a proportion of these individuals, in association with antihistaminic and broncho-dilatators and under close clinical surveillance. [15] [16] [17] [18] [19] [20] We report here the largest series of 513 poorly mobilizing adult patients, with a variety of malignancies, who received ancestim plus filgrastim following one or several previous failed attempts with G-CSF; French investigators took advantage of the compassionate program allowing access to this drug. We further report that SCF can be successfully and safely used in this subset of patients.
Patients and methods

Patients
A total of 550 adult patients were considered as poor mobilizers, because less than 2 Â 10 6 CD34 þ cells/kg were collected during one or several attempts at mobilization/ apheresis with standard mobilization regimens. They benefited from a French compassionate program ('Autorisation Temporaire d'Utilisation, ATU nominative' or individual temporary authorization for use) over a 10-year period, between April 1998 and July 2007. The program Autorisation Temporaire d'Utilisation was delivered by the French Health Regulatory Authority (AFSSaPS, Agence Franc¸aise de Se´curite´Sanitaire) on an individual basis, in compliance with the criteria defined by the Groupe de Travail sur les Me´dicaments Anti-Cance´reux (a working group at AFSSaPS, which defines acceptable and nonacceptable use of anticancer agents, using an evidencebased approach). These patients were candidates for high-dose chemotherapy and autologous transplantation, for stage II/III multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, refractory chronic lymphocytic leukaemia, stage IV neuroblastoma, Ewing's sarcoma, testis cancer or ovarian cancer.
Data on treatment administration, tolerance, mobilization and collection were available for 513 of these 550 registered patients (93.3%), and are presented in this report. Patients' characteristics are described in Table 1 . Among these 513 patients, 394 (77%) had total failure (no apheresis) and 119 (23%) had partial failure (one or several aphereses were performed, but yielded insufficient numbers of progenitors) after mobilization and collection attempts. A total of 2, 7, 25, 165 and 314 patients had had, respectively, 5, 4, 3, 2 and 1 previous mobilization/ collection attempts when they received SCF. The peak mean value of CD34 þ cells at the last mobilization attempt before ancestim use was 5.75/mL (SD 5.74).
Ancestim administration r-metHuSCF used in this setting was produced using E. coli, genetically engineered to express a methionineterminated recombinant version of human SCF (ancestim: Stemgen, Amgen Inc, Thousand Oaks, CA, USA). Ancestim was provided by Amgen, on acceptance by AFSSaPS of an ATU for designated patients; data were reported to AFSSaPS and Amgen (through a clinical research organization). Filgrastim (Neupogen, Amgen Inc) is also an E. coli-genetically engineered recombinant protein. The administration of r-metHuSCF (20 mg/kg/day, s.c.) was given with premedication that included daily ranitidine p.o. (started 24 h before initiation of ancestim), cetririzine HCl p.o. and salbutamol sulphate inhalation shortly before each of the ancestim s.c. injections. Health-care personnel were instructed to exclusively administer ancestim through s.c. injections. The combination of cytokines was administered either after blood count recovery following the last cycle of anticancer treatment (in this case, the prescribed dose of filgrastim was 10 mg/kg/d), or starting on day 1 after myelosuppressive chemotherapy (in this case, the prescribed dose of filgrastim was 5 mg/kg/d); the clinical investigator filing the ATU with AFSSaPS was responsible for the choice of the mobilization regimen. In all, 57% of patients received ancestim combined with filgrastim (10 mg/kg/day) for a median of 6 days (range: 2-21); the Figure 1 ).
Ancestim (r-metHuSCF) for poorly mobilizing patients V Lapierre et al other patients received chemotherapy followed by ancestim combined with filgrastim (5 mg/kg/day) for a median of 11 days (range: 1-33), similar to practices described in previous reports. 16 Biological monitoring of mobilization and peripheral blood collections Peripheral blood CD34 þ cell counts, aphereses and CD34 þ cell counts in collected cell products were determined at each of the 64 centres that reported data, according to local standard operating procedures. Our report summarizes results observed in individual cases and centres; thus, there was no attempt to standardize medical and laboratory practices in clinical, collection and processing facilities. However, French regulations apply to the processing facilities that are authorized by AFSSaPS, which participate in a nationwide annual survey on CD34 þ cell enumeration, thus ensuring the standardization of collection, processing and quality control procedures performed in these facilities. 21 Aphereses were conducted as per standard operating procedures of French centres , in which collection facilities tend to process a minimum of two total blood volumes when patients poorly mobilize.
Statistical analyses
Continuous variables are presented by median and range, and categorical variables by frequency and percentage. The analysis of factors associated with collection of CD34 þ cell numbers above 2 Â 10 6 /kg and the analysis of factors associated with proceeding to autologous transplantation were performed by logistic regression. Multiple logistic regression with stepwise selection was used to identify independent factors associated with CD34 þ cell numbers above 2 Â 10 6 /kg and autologous transplantation. The factors included in the multivariate analysis were those with a P-value lower than 0.20 in univariate analysis. Associations were described by odds ratio with 95% confidence interval. All P-values were based on a twosided hypothesis. Analyses were performed using SAS 9.1 software.
Results
Ancestim is well tolerated in poorly mobilizing patients Information on toxicity was available for 508 of the 513 observed patients. Most patients experienced reversible grade I-II toxicities despite premedication with antihistamine agents and broncho-dilatators. In all, 66% of the patients experienced a local reaction at the site of injection. Other toxicities were reported in 16.5% (84 of 508) of treated patients; some of the symptoms experienced include diffuse erythema (12%), bone or joint pain (8%), influenzalike syndrome (4%), fever (3%), moderate oedema (2%), pruritus (1%) and vomiting (1%). Ancestim was not discontinued, and patients proceeded to blood CD34 þ cell enumeration and eventual apheresis.
Severe adverse events were reported for 12 (2.4%) patients; all but one were grade III. Two of the 12 patients inadvertently received ancestim through the i.v. route, despite recommendations for s.c. administration; these two patients developed grade III mast-cell-mediated toxicities, and the drug was discontinued. Three other patients developed severe but reversible pharyngo-laryngeal oedema with hypotension. Three patients experienced dyspnea, in one of whom was documented interstitial pneumonia. Three patients presented with neurological symptoms (epilepsy, syncope, facial palsy), one of which was rapidly fatal (epilepsy, with documented central nervous system localization); it was unclear whether ancestim or tumour progression was partly or totally responsible for the clinical symptoms in the other two individuals. One patient developed acute and reversible hepatic cytolysis of probably toxic origin, as suggested by histological analysis of a liver biopsy. In all cases, ancestim was immediately stopped, and the collection was abandoned. With the exception of the one death mentioned above, all these events were reversible without sequelae, with a follow-up of 6 months.
Ancestim combined with filgrastim allows for adequate mobilization and collection in approximately 40% of poorly mobilizing patients A total of 235 patients (46%) did proceed to apheresis following mobilization with an ancestim-based regimen (Table 2) . Peripheral blood CD34 þ counts reached a median number of 19.1 mL (range: 0.1-145.0) for these patients. A median number of two aphereses were performed (range: 1-6). The median number of collected CD34 þ cells was 3.00 Â 10 6 /kg (range: 0.03-39.50). The procedure allowed the collection of a cumulative number of CD34 þ cells above 2 Â 10 6 /kg in 161 patients. This represents 68.5% of patients in whom collection was performed and in 31% of all individuals in this survey (30% of patients with no previous collection, 36% of those with insufficient numbers of previously collected cells; the proportion was identical whether patients had previously had one, two, three or four attempts at mobilization/ collection; none of the two patients who had five previous Ancestim (r-metHuSCF) for poorly mobilizing patients V Lapierre et al attempts at mobilization/collection were apheresed following SCF administration); 74 additional patients were apheresed, which resulted in ancestim-mobilized peripheral blood progenitor cell grafts with less than 2 Â 10 6 CD34 þ cells/kg; 46 of these patients finally underwent intensive chemotherapy and autologous transplantation with a combination of several autologous peripheral blood progenitor cell collections or of peripheral blood progenitor cell collection with marrow collection ( Figure 1) ; in total, 207 out of 513, that is, 40% of the patients, proceeded to autologous transplantation and received a graft that was obtained exclusively or partially after an ancestim-based mobilization regimen.
A total of 278 patients were not apheresed, as their peripheral blood CD34 þ cell counts remained low: 3 (range: 0-15) CD34 þ cells/mL. Table 3 presents the results of the variables that correlated with collection success. Diagnosis, previous treatments (numbers of previous chemotherapy cycles, previous high-dose chemotherapy supported by autologous transplantation), the number of previous failed attempts at mobilization, the type of procedure used in previous collection attempts and the type of mobilization procedure, along with ancestim and its duration, significantly affected the success of ancestim mobilization. In multivariate analysis, factors independently associated with mobilization and transplantation success were diagnosis (patients with multiple myeloma had a higher probability of success than did patients with lymphoma), the absence of previous high-dose chemotherapy supported by autologous transplantation, no more than one previous failed attempt and patients who had received a mobilization regimen including cytotoxic agents (cyclophosphamide or others). 
Discussion
We report here that the combination of ancestim with filgrastim allowed successful mobilization and collection of CD34 þ progenitors in the peripheral blood of approximately one-third of patients who failed previous attempts at mobilization and collection. An insufficient number of autologous blood progenitors can compromise the use of an efficacious systemic therapy program that includes highdose chemotherapy as a final consolidation step. Thus, identifying agents to improve stem and progenitor cell mobilization in peripheral blood is an important issue.
The use of ancestim in poorly mobilizing patients was previously reported for several small groups of patients. Patients who had been heavily pretreated for Hodgkin's or non-Hodgkin's lymphoma mobilized more efficiently in response to ancestim plus filgrastim than to filgrastim alone. 15 A higher success rate was reported in two small subgroups of heavily pretreated patients. 16, 17 Dawson et al. 18 reported a 38% success rate in poorly mobilizing patients treated for malignant blood diseases, mostly lymphoid neoplasms. Herbert et al. 19 recently reported an improved rate of collection success in patients with chronic Ancestim (r-metHuSCF) for poorly mobilizing patients V Lapierre et al lymphoid leukaemia who were previously treated with fludarabine. Our data further extend these observations to a larger and more diverse population of patients, with a variety of malignancies; although, expectedly, most of the cases were multiple myeloma and lymphomas, because of current practices for the use of high-dose chemotherapy and autologous transplantation, a small subset of individuals treated for sarcomas, as well as for testis or ovarian cancers, was also included in our study.
Observations from this large cohort of patients suggest that variables that are positively or negatively associated with the success of mobilization with G-CSF also predict to some extent the success or failure of an ancestim-based mobilization regimen (and subsequent autologous transplantation); these variables include diagnosis (myeloma patients mobilize their hematopoietic progenitors better than do patients with other diagnoses), cumulative and previous treatments (having already received an intensive chemotherapy regimen supported by autologous transplantation), previous insufficient collection of an autologous blood graft in response to a standard mobilization regimen and the use of ancestim and filgrastim in combination with a myelosuppressive chemotherapy rather than by themselves. Conversely, tumour response was not a predictor of success for ancestim mobilization, as there was a nonsignificant excess of patients in PR in the 'success' group: this is probably the consequence of the higher rate of mobilization success in patients with multiple myeloma, whereas only a minority of these patients obtain complete remission before receiving high-dose melphalan and autologous transplantation.
Choice of mobilizing agents is limited, 22 as many hematopoietic growth factors and cytokines are not or are no longer available for clinical use. 23 The use of biosimilars 24, 25 or of a pegylated and long-lasting form of rhG-CSF 26, 27 is unlikely to significantly improve the 'mobilization index'. Parathyroid hormone was even tested in a phase I trial for mobilization, and was well tolerated, with successful collection in 9 out of 20 poorly mobilizing patients. 28 In addition, administration of recombinant human growth hormone plus G-CSF was associated with 13 of 15 successful collections compared with none with G-CSF alone in patients who had failed one previous attempt. 29 Recently, drugs targeting the CXCR-4/CXCL12 axis showed interesting results. Plerixafor has been tested in several clinical studies, which demonstrated its efficacy on progenitor cell collection when used upfront in combination with G-CSF in healthy volunteers 30, 31 or in patients with lymphoid malignancies. [32] [33] [34] [35] In addition, several studies reported the use of plerixafor in poorly mobilizing patients, with a success rate ranging from 66 to 85% in small-to medium-sized patient groups. [9] [10] [11] [12] On the basis of these findings, plerixafor is being used more widely in clinical practice. 36, 37 Nevertheless, no direct comparison data between plerixafor and ancestim are currently available in poorly mobilizing patients. Patients in our cohort were heavily pretreated, and may differ from patients who received plerixafor in the above-mentioned studies. Finally, one-fourth to one-third of patients who were candidates for autologous blood cell collection and transplantation experienced failure after treatment with G-CSF and plerixafor; this situation leaves room for further improvement.
In conclusion, this large French survey of individuals who were candidates for high-dose chemotherapy and autologous transplantation suggests that the use of SCF can benefit a significant proportion of poorly mobilizing patients. Ancestim (r-metHuSCF) for poorly mobilizing patients V Lapierre et al
